Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Irinotecan + Tulmimetostat |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
Tulmimetostat | CPI0209|CPI-0209|CPI 0209 | EZH1 inhibitor 5 EZH2 inhibitor 20 | Tulmimetostat is a second-generation inhibitor of EZH1 and EZH2, which may lead to decreased tumor growth (J Clin Oncol 41, 2023 (suppl 16; abstr 3094)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04104776 | Phase Ib/II | Tulmimetostat Irinotecan + Tulmimetostat | A Study of CPI-0209 in Patients With Advanced Solid Tumors | Recruiting | USA | POL | ITA | GBR | FRA | ESP | 1 |